Literature DB >> 33532490

The Value of Combined Detection of D-dimer and CD62p in Judging the Severity of Acute Cerebral Infarction and Short-Term Prognosis.

Min Xu1, Xiao-Ying He2, Pan Huang3.   

Abstract

OBJECTIVE: To explore the value of combined detection of peripheral blood P-selectin (CD62p) and D-dimer (D-dimer) in the judgment of acute cerebral infarction severity and short-term prognosis.
METHODS: 268 patients with acute cerebral infarction from February 2015 to February 2019 were selected as the observation group. According to the National Institute of Health stroke scale, there were 90 cases (SCI group), 88 cases (MOCI group), and 90cases (MICI group) in the severe, moderate, and mild cerebral infarction groups, respectively. In the same period, 80 cases of healthy people served as the Normal group. Use flow cytometry to detect CD62p in peripheral blood and magnetic bead method to detect D-dimer level within 24 hours of onset. Logistic regression was used to analyze whether the two are factors affecting the short-term prognosis of acute cerebral infarction, and the ROC curve was drawn to evaluate the value of the combined detection of the two in the short-term prognosis of patients with acute cerebral infarction.
RESULTS: Peripheral blood D-dimer and CD62p levels (2.95 ± 0.76 ng/l, 34.03 ± 5.29 ng/l) in the SCI group were higher than those in the MOCI group (2.30 ± 0.51 ng/l, 27.58 ± 5.56 ng/l) and the MICI group (1.87 ± 0.40 ng/l, 19.60 ± 3.98 ng/l); the difference between the groups was statistically significant (P < 0.05). Logistic regression analysis showed that D-dimer and CD62p were independent risk factors affecting the poor prognosis of patients with acute cerebral infarction (OR values were 3.752 and 1.213, and 95% CI were 1.612-7.934 and 1.093-1.342, respectively, both P < 0.05). The AUC of D-dimer combined with CD62p for predicting poor prognosis of acute cerebral infarction is 0.859, which is better than D-dimer and CD62p alone.
CONCLUSION: Peripheral blood D-dimer combined with CD62p detection is helpful for the risk stratification and short-term prognosis assessment of patients with acute cerebral infarction. Clinical detection is of great significance for the prevention and monitoring of disease development.
Copyright © 2021 Min Xu et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33532490      PMCID: PMC7834744          DOI: 10.1155/2021/6620311

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  17 in total

1.  Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels.

Authors:  H Tohgi; S Konno; S Takahashi; D Koizumi; R Kondo; H Takahashi
Journal:  Thromb Res       Date:  2000-12-01       Impact factor: 3.944

2.  Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis.

Authors:  Dimitrios Sagris; Georgios Georgiopoulos; Ioannis Leventis; Konstantinos Pateras; Lesly A Pearce; Eleni Korompoki; Konstantinos Makaritsis; Konstantinos Vemmos; Haralampos Milionis; George Ntaios
Journal:  Neurology       Date:  2020-07-06       Impact factor: 9.910

3.  Validation of the age-adjusted D-dimer in an ambulatory deep vein thrombosis diagnostic service: beware of superficial thrombophlebitis.

Authors:  Elizabeth Soyode; William Pritchard; Megan Hayman; Annie Davenport; Pasupathy Sivasothy; Will Thomas
Journal:  Br J Haematol       Date:  2020-09-10       Impact factor: 6.998

4.  [Changes of plasma CD62p levels in patients with acute cerebral infarction].

Authors:  Xiao-Song Huang; Qi-Dong Yang; Yun-Hai Liu; Zun-Jing Liu
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2004-08

5.  20-Hydroxyeicosatetraenoic Acid as a Predictor of Neurological Deterioration in Acute Minor Ischemic Stroke.

Authors:  Xingyang Yi; Zhao Han; Qiang Zhou; Jing Lin; Ping Liu
Journal:  Stroke       Date:  2016-11-10       Impact factor: 7.914

6.  Prognostic Metrics Associated with Inflammation and Atherosclerosis Signaling Evaluate the Burden of Adverse Clinical Outcomes in Ischemic Stroke Patients.

Authors:  Daoxia Guo; Zhengbao Zhu; Chongke Zhong; Aili Wang; Xuewei Xie; Tan Xu; Yanbo Peng; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Jing Chen; Liping Liu; Yilong Wang; Jiang He; Yonghong Zhang
Journal:  Clin Chem       Date:  2020-11-01       Impact factor: 8.327

7.  P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion.

Authors:  Y Okada; B R Copeland; E Mori; M M Tung; W S Thomas; G J del Zoppo
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

8.  ASC regulates platelet activation and contributes to thrombus formation independent of NLRP3 inflammasome.

Authors:  Sachiko Watanabe; Fumitake Usui-Kawanishi; Takanori Komada; Tadayoshi Karasawa; Ryo Kamata; Naoya Yamada; Hiroaki Kimura; Katsuya Dezaki; Tsukasa Ohmori; Masafumi Takahashi
Journal:  Biochem Biophys Res Commun       Date:  2020-08-08       Impact factor: 3.575

Review 9.  Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges.

Authors:  Tiandong Leng; Zhi-Gang Xiong
Journal:  Brain Circ       Date:  2019-03-27
View more
  3 in total

1.  Clinical Effect of Butylphthalide Combined with Rt-PA Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction.

Authors:  Xiangchen Zhou; Jundong Yang; Lihua Liu; Yingying Zhu
Journal:  Appl Bionics Biomech       Date:  2022-06-17       Impact factor: 1.664

2.  Intravenous Thrombolysis Combined with Arterial Thrombolysis (Bridging Therapy) Effectively Improves Vascular Recanalization Rate in Patients with Cerebral Infarction.

Authors:  Junting Huo; Wei Li; Yu Liu
Journal:  J Immunol Res       Date:  2022-07-26       Impact factor: 4.493

3.  A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction.

Authors:  Zongqin Li; Xiaoxia Rong; Jun Luo; Tao Zeng; Pan Huang; Xuejie Xu
Journal:  Biomed Res Int       Date:  2021-06-29       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.